Clinical and biological markers in gastric cancer: update and perspectives.
Gastric cancer is the second cause of death from cancer worldwide and the only chance to reach better outcomes lays on an early diagnosis. The need for non-invasive, low-cost tests is invoked also in countries in which imaging and endoscopic screening have already showed the ability to improve early diagnosis and overall survival. Genomic medicine could allow a better understanding of regulatory pathways driving the development and growth of gastric cancer and the characterization of specific molecular targets actually stimulate new drug developments. The knowledge of the role of Helicobacter pylori (HP) in gastric tumor pathogenesis has put new insides in the understanding of this peculiar disease and enriched the field of gastric biomarkers.
Cappellani
Alessandro
A
Department of Surgery, General and Breast Surgery Unit, University of Catania, University Hospital of Catania, Catania, Italy. alecap@unict.it
Zanghi
Antonio
A
Di Vita
Maria
M
Zanet
Ernesto
E
Veroux
Pierfrancesco
P
Cacopardo
Bruno
B
Cavallaro
Andrea
A
Piccolo
Gaetano
G
Lo Menzo
Emanuele
E
Murabito
Paolo
P
Berretta
Massimiliano
M
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000382:microbiology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D055088:Early Detection of Cancer / Q000379:methods; D016480:Helicobacter pylori / Q000737:chemistry*; D006801:Humans; D053842:Microsatellite Instability; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000382:microbiology*; D037521:Virulence Factors / Q000378:metabolism*
D014408:Biomarkers, Tumor; D037521:Virulence Factors